EIF4G1 and neoplasm: H&E and Ki67 labelling revealed that these EIF4G1 inhibitors caused extensive necrosis within NSCLC tumour tissues and the obvious inhibition of tumour cell proliferation, when compared to the vehicle treatment controls (Figure 3E‐F).